retatrutide erectile dysfunction Retatrutide: Evidence, Safety & Options Retatrutide UK 2026: Phase 3

Mitochondrial bax translocation accelerates DNA fragmentation and cell necrosis in a murine model of acetaminophen hepatotoxicity

This is however, considered to be an off-label use , because GLP-1 agonists are typically prescribed for those with type 2 diabetes, obesity, or medical concerns

This blog post takes a deep dive into what this means for patients, separating fact from fear, and helping you understand how to balance the benefits and risks of GLP-1 therapy

Other research published this week raises questions about the effects of GLP-1s taken around the time of pregnancy

As of June 2026, retatrutide (Eli Lillys LY-3437943) has not been approved by any drug regulator, including the US FDA and the Australian TGA